Clinical Trial Update: A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three doses of AZD7594 inhaled once daily for 14 days in mild to moderate asthma; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• AZD7594

Snippet

Sponsor: AstraZeneca | Conditions: Asthma, Efficacy | Phase 2 | Status: COMPLETED | Results posted: 2017-06-23